Brand & Product Security

With partial support from manufacturers themselves, home health services are emerging as a critical channel for specialties

Oncology combines some of the most life-changing therapeutic events with the most complex commercialization pathways. Rising costs of treatments simply add to the tension

As FDA makes progress on an active surveillance system, drug manufacturers and third-party drug safety vendors navigate their own set of challenges

But the global picture is sunny as most of the global market growth benefits the generic makers

Even as diagnosed (and “prediabetes”) cases rise worldwide, healthcare providers struggle with patients to control the course of the disease. New therapies—and new health services—are aiding in the battle

Trends in site selection, regional economic development and business expansion

A looming crisis in drug-resistant anti-infectives is not being met with a commensurate industry effort. Governments and industry are trying to cope

As hundreds of candidate drugs receive official “orphan” status, the Orphan Drug Act gets re-examined. Meanwhile, these drugs are driving the growth of specialty pharmacy

The 2010 PDMA Sharing Conference: Expanding Our Focus With More Learning Opportunities

Industry’s coming challenges will force dramatic change on how products are brought to market and businesses are sustained. Industry leaders have already started the process

Faced with fierce competition, dwindling budgets and intense pressure to create jobs, economic development authorities are reinventing their recruitment strategies to attract life sciences employers

Patient Outcomes Research Moves Drug Development Beyond Clinical Results

‘Print on demand’ changes traditional design, production and inventory practices for labels, inserts and other printed packaging

While nurses move into a more central role in prescribing and administering pharmaceuticals, the nursing professions debate industry influence

As legislative mandates have receded, manufacturers must undertake their own initiatives for protecting against counterfeits and diversion

Central nervous system (CNS) medication for society’s oldest and youngest present special challenges

Antipsychotic and antidepressant drugs have risen to the top categories of prescribed medications in a challenging and risky medical and regulatory arena

States continue to push for a ‘bio-economic’ foundation

States continue to push for a ‘bio-economic’ foundation

Drugmakers recalibrate anti-counterfeiting and serialization efforts

Mature product franchises and mixed clinical outcomes have not dissuaded pharma companies from expending marketing resources for cardiovascular disease treatment

Biopharmaceutical manufacturers turn to a direct-distribution model to leverage opportunities for cost-effective drug delivery and personalized health management services